Report date: Wednesday, August 5, 2026 (before market open) | Call: 10:00 AM ET
LLY enters this report as one of the market's largest companies, having ridden the obesity/incretin boom to a roughly $1 trillion valuation. The stock has been volatile in recent weeks: shares ran from the high-$1,100s in June to a 2026 high near $1,236 in early July on strong sentiment around the oral GLP-1 launch and retatrutide data, but have since pulled back to roughly $1,115-$1,150 heading into the print, including a notable drawdown on July 30 tied to a widely-read piece questioning the company's capital-allocation options given its cash pile.
Options/consensus pricing suggests real uncertainty about this quarter. According to one earnings preview, Wall Street expects Eli Lilly to report second-quarter earnings of $6.55 per share on revenue of $20.69B, with the consensus view reflecting input from 21 analysts and EPS estimates spanning a wide range from $5.28 to $9.08, signaling considerable uncertainty around the company's near-term profitability trajectory. Other trackers show similar but not identical numbers — one preview pegs consensus at $20.5B revenue and $7.74 EPS, another at $6.71 per share... a year-over-year increase of 6.3%, with revenues expected to be $20.26 billion, up 30.2% from the year-ago quarter, and a third at "$6.06 per share and revenue of $20.6851 billion." The dispersion itself is a story: analyst conviction has deteriorated sharply in recent months, with the consensus EPS estimate falling 25.7% over the past thirty days, down from $8.82, and down 19.0% over the past ninety days from $8.09. That kind of downward drift heading into a print from a company with LLY's beat history is worth watching closely — it suggests the Street sees rising cost/price headwinds that may not be fully reflected in guidance yet.
Importantly, Lilly has a strong recent beat record: Eli Lilly beat analysts' revenue expectations last quarter, reporting revenues of $19.8 billion, up 55.5% year on year — a stunning quarter with a beat of analysts' EPS estimates and an impressive beat of full-year EPS guidance. But the comp gets harder: the market is expecting Eli Lilly's revenue to grow 32.5% year on year, slowing from the 37.6% increase it recorded in the same quarter last year.
Lilly's Q1 2026 (reported April 30) was a blowout that raised the bar for the rest of the year:
That guidance raise, plus the subsequent FDA approval and launch of Foundayo (orforglipron) — the first oral GLP-1 approved for obesity — is the backdrop against which Q2 will be judged.
1. Foundayo (oral GLP-1) launch trajectory. This is arguably the single most important storyline. Foundayo became broadly available in early April, and Q1 commentary described "encouraging" early metrics (prescriber counts, new-to-class share, LillyDirect mix) but cautioned it was very early. Analysts will want hard Q2 numbers on prescription volume, payer access progress, and the ramp of the direct-to-consumer TV campaign, which management said would ramp meaningfully starting in Q3. One preview specifically flags the initial commercial ramp of Foundayo, including prescription volumes, channel mix (LillyDirect, PBMs, Medicare), and new-to-class patient starts, alongside continued volume growth and market share for Mounjaro and Zepbound as the top watch items.
2. Mounjaro/Zepbound volume vs. price. The core incretin franchise remains the growth engine. Watch for continued U.S. and international volume strength against the backdrop of price/mix headwinds, especially as management has guided to low to mid-teens price erosion for FY26. Internationally, Mounjaro has become the market leader outside the U.S., and the question is how much more share is available versus reliance on patient activation/market growth (management noted diminishing returns on incremental share once above ~50% OUS share).
3. Medicare Bridge program ramp. The CMS GLP-1 Bridge pilot — capping beneficiary out-of-pocket costs at $50/month for eligible Medicare patients with BMI >35 or obesity-related comorbidities — began no later than July 1 and could open access to as many as 20 million eligible beneficiaries. This is a Q3-skewed catalyst, but Q2 commentary on early enrollment/prior-authorization dynamics will matter for 2H26 and 2027 modeling.
4. Novo Nordisk advertising lawsuit. An overhang investors will ask about: Novo Nordisk sued Lilly in federal court alleging false-advertising violations tied to head-to-head dosing comparisons between Zepbound/Mounjaro and Wegovy/Ozempic, and has sought a preliminary injunction to halt the ads. Lilly has denied wrongdoing and says its campaigns are truthful and evidence-based. This is a legal/reputational risk rather than a near-term financial one, but management will likely be asked for an update on the case's status and any ad-spend implications.
5. Retatrutide and pipeline momentum. Retatrutide (the GGG "triple agonist") has posted a string of positive Phase 3 readouts (TRIUMPH and TRANSCEND programs) and management has now said it plans to file for FDA approval in Q1 2027 — later than some hoped, but with a full five-trial Phase 3 package. In late-stage obesity trials, the drug showed weight loss averaging 28% over 80 weeks at the highest doses in some reporting, well above current-generation therapies. Expect further color on retatrutide's competitive positioning (severely obese/high-need patients) and on eloralintide (amylin agonist) Phase 3 progress, both flagged as watch items in previews (updates on retatrutide and eloralintide clinical programs and broader pipeline momentum).
6. Capital allocation / M&A pace. Lilly has been unusually acquisitive in 2026 — deals for Orna Therapeutics, Centessa Pharmaceuticals, Kelonia Therapeutics, Ajax Therapeutics, and most recently a deal to acquire psychedelic-medicine developer AtaiBeckley for up to $3.8 billion (an initial $2.8 billion, $6.75/share cash plus contingent value rights) to bolster its depression/mental-health pipeline. This ties into a broader debate — highlighted in recent commentary — about how Lilly deploys the roughly $17 billion of excess cash it's expected to generate this year (and >$31 billion projected for 2027), given that buybacks look expensive at Lilly's premium valuation versus peers like Merck. Investors should listen for tone on further BD activity and buyback pace, plus any preview of the December 7 Investor Community Meeting.
| Metric | Q1 2026 Actual | Q2 2026 Consensus (varies by source) |
|---|---|---|
| Revenue | $19.8B (+56% YoY) | ~$20.3–$20.7B (+~30-33% YoY) |
| Non-GAAP EPS | $8.55 | ~$6.06–$7.74 (wide dispersion) |
| FY2026 Revenue Guide | $82.0–$85.0B | Watch for another raise/reaffirm |
| FY2026 Non-GAAP EPS Guide | $35.50–$37.00 | Watch for another raise/reaffirm |
The wide spread in EPS estimates (from ~$5.28 to over $9.00 per one source) reflects genuine Street disagreement about how much acquired-IPR&D charges (which have swung EPS by $0.50-$1.70+ in recent quarters), price erosion, and Foundayo launch investment will weigh on the quarter — meaning the "beat or miss" narrative may hinge as much on mix and one-time items as on core operating momentum.
The fundamental growth story — Mounjaro, Zepbound, and now Foundayo driving industry-leading volume growth — remains intact, and Lilly has beaten estimates repeatedly through this cycle. The key swing factors for tomorrow's report are: (1) how fast Foundayo is actually ramping versus the "encouraging but early" tone from Q1, (2) whether price erosion is tracking to the low-mid-teens guide or worsening, (3) any incremental read on Medicare Bridge uptake, and (4) management's tone on the Novo Nordisk litigation and the ever-expanding M&A/capital-allocation strategy. Given the stock's ~10% pullback from July highs and the unusually wide analyst estimate dispersion, this print carries more volatility risk than Lilly's recent "clean beat" quarters — but the multi-year growth algorithm (oral GLP-1 scaling, retatrutide/eloralintide pipeline, international incretin expansion) remains the core long-term thesis regardless of one quarter's print.